CORRECTION article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Correction: Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis
Provisionally accepted
- Obstetrics & Gynaecology, The Chinese University of Hong Kong, Shatin, New Territories, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Keywords: Endometriosis, myeloid-derived suppressor cells, Sunitinib, Immunosuppression, gene expressions
Received: 07 Nov 2025; Accepted: 12 Nov 2025.
Copyright: © 2025 Wang, He, Hung, Liang, Zhang, Gao, Chu, Zhang, Xu and Chung. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chi Chiu Wang, ccwang@cuhk.edu.hk
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.